Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04955808 | Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery | suspended | — | 2,400 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT05036226 | COAST Therapy in Advanced Solid Tumors and Prostate Cancer(COAST) | recruiting | Phase 1 / Phase 2 | 76 | Medical University of South CarolinaOTHER | 1 |
| May 13, 2026 |
| clinicaltrials |
| NCT05638295 | Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) | active not recruiting | Phase 2 | 105 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT06223542 | Studying TAK-243 in Patients With Advanced Cancer | recruiting | Phase 1 | 95 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT06385496 | Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT06390865 | Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) | active not recruiting | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT06400225 | Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT06673329 | Brodalumab in the Treatment of Immune-Related Adverse Events | recruiting | Phase 1 | 11 | Brian Henick, MDOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06956248 | Innovating Access to Novel Therapies Through Standardized Prospective Integration of Response Evaluations (IMPACT-INSPIRE)(IMPACT-INSPIRE) | recruiting | — | 50 | National Cancer Centre, SingaporeOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07390383 | A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04] | recruiting | Phase 2 | 110 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT07582822 | JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC | not yet recruiting | Phase 1 | 60 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07583771 | A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma | not yet recruiting | Phase 1 | 186 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT07583953 | An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors | not yet recruiting | Early Phase 1 | 50 | Suzhou Abogen Biosciences Co., Ltd.INDUSTRY | 0 | May 13, 2026 | clinicaltrials |
| NCT05038839 | Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors | completed | Phase 1 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05162755 | S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers | completed | Phase 1 | 41 | Institut de Recherches Internationales ServierOTHER | 2 | May 12, 2026 | clinicaltrials |
| NCT05385965 | Meaning-Centered Pain Coping Skills Training for Cancer Pain(MCPC) | completed | N/A | 211 | Duke UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05438329 | First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 1,123 | DualityBio Inc.INDUSTRY | 3 | May 12, 2026 | clinicaltrials |
| NCT05582850 | DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours(EPRAD) | terminated | Phase 1 | 29 | Domain Therapeutics SAINDUSTRY | 2 | May 12, 2026 | clinicaltrials |
| NCT04502602 | Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer(iNNOVATE) | active not recruiting | Phase 1 | 18 | Virginia Commonwealth UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05076396 | PM14 Administered Intravenously to Patients With Advanced Solid Tumors | completed | Phase 1 | 126 | PharmaMarINDUSTRY | 3 | May 11, 2026 | clinicaltrials |
| NCT06474455 | A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 156 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT06487858 | A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors | terminated | Phase 1 | 42 | BeOne MedicinesINDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT07332312 | A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Indian and Alaska Native Cancer Patients Living in Rural California | recruiting | N/A | 71 | University of Southern CaliforniaOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07563972 | Intratumoral Macrophage Exosomes With Mechanobiological Reprogramming for Advanced Solid Tumors | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07577206 | Single Microdose Trial- CXCR4 PET Tracer - Pharmacokinetics and Pharmacodynamics of [68Ga]Ga-R54, a Radiopharmaceutical Directed Toward CXCR4 in Patients With Advanced Solid Neoplasia. | recruiting | Early Phase 1 | 10 | National Cancer Institute, NaplesOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04439110 | Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q) | active not recruiting | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | May 8, 2026 | clinicaltrials |
| NCT05265091 | A Study of KL590586 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 414 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT05367635 | A Study of SKB315 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 246 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT05387928 | A Study of KL340399 in Patients With Advanced Solid Tumors | completed | Phase 1 | 21 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT05549804 | A Study of Intratumoral KL340399 in Patients With Advanced Solid Tumors | completed | Phase 1 | 6 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT05954312 | A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 290 | Vividion Therapeutics, Inc.INDUSTRY | 3 | May 8, 2026 | clinicaltrials |
| NCT06380816 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 167 | Cancer Research UKOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06428331 | A Study of SKB518 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 150 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06725758 | A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours(TEADES) | recruiting | Phase 1 / Phase 2 | 315 | Orion Corporation, Orion PharmaINDUSTRY | 6 | May 8, 2026 | clinicaltrials |
| NCT06736327 | A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 180 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06826040 | SKB445 for Injection in Solid Tumors | recruiting | Phase 1 | 126 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT07087197 | A Study of SKB107 in Advanced Solid Tumors With Bone Metastases | recruiting | Phase 1 | 90 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT07220447 | L-Theanine to Support Relaxation and Mood for Cancer Patients in Surveillance | recruiting | Early Phase 1 | 50 | City of Hope Medical CenterOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07380386 | SKB105 for Injection in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 256 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT01705548 | Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis | completed | N/A | 24 | Emory UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04439266 | Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F) | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 7, 2026 | clinicaltrials |
| NCT04439279 | Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 7, 2026 | clinicaltrials |
| NCT04439331 | Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 7, 2026 | clinicaltrials |
| NCT04439344 | Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) | active not recruiting | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | May 7, 2026 | clinicaltrials |
| NCT06555744 | A Study of ZW191 in Participants With Solid Tumors | active not recruiting | Phase 1 | 145 | Zymeworks BC Inc.INDUSTRY | 6 | May 7, 2026 | clinicaltrials |
| NCT06726369 | A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 90 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT06761417 | A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults | recruiting | Phase 2 | 49 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06795815 | The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic Disease(OHGW-ACP) | recruiting | N/A | 75 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | May 7, 2026 | clinicaltrials |
| NCT06926751 | Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors | recruiting | Phase 2 | 132 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 7, 2026 | clinicaltrials |
Data updated 24 days agoSource updated May 13, 2026source: clinicaltrials